• Search
  • Advanced Search

Review

October 2, 2024


Roles of X-box binding protein 1 in liver pathogenesis
Jihoon Tak, Yun Seok Kim, Sang Geon Kim
Clin Mol Hepatol. 2025;31(1):1-31.

The prevalence of drug-induced liver injury (DILI) and viral liver infections presents significant challenges in modern healthcare and contributes to considerable morbidity and mortality worldwide. Concurrently, metabolic dysfunctionassociated steatotic liver...

Review

October 2, 2024


Sinusoidal communication in chronic liver disease
Albert Gibert-Ramos, María Andrés-Rozas, Raül Pastó, et al.
Clin Mol Hepatol. 2025;31(1):32-55.

The liver sinusoid, mainly composed of liver sinusoidal endothelial cells, hepatic macrophages and hepatic stellate cells, shapes the hepatic vasculature and is key to maintaining liver homeostasis and function. During...

Review

October 21, 2024


Bioactive metabolites: A clue to the link between MASLD and CKD?
Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, et al.
Clin Mol Hepatol. 2025;31(1):56-73.

Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the...

Review

October 23, 2024


Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations
Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, et al.
Clin Mol Hepatol. 2025;31(1):74-89.

One-third of adults across the globe exhibit metabolic dysfunction-associated steatotic liver disease (MASLD)―formerly known as nonalcoholic fatty liver disease (NAFLD). To date, MASLD is the fastest-growing etiology of chronic liver...

Review

November 11, 2024


Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment
Atsumasa Komori, Yuki Kugiyama
Clin Mol Hepatol. 2025;31(1):90-104.

Patients with hard-to-treat autoimmune hepatitis (AIH) or primary biliary cholangitis (PBC) are defined a posteriori as those who do not show a sufficient response or are intolerant to pharmacological treatments,...

Original Article

July 11, 2024


Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
Chuan Liu, Hong You, Qing-Lei Zeng, et al.
Clin Mol Hepatol. 2025;31(1):105-118.

Backgrounds/Aims: Non-invasive models stratifying clinically significant portal hypertension (CSPH) are limited. Herein, we developed a new non-invasive model for predicting CSPH in patients with compensated cirrhosis and investigated whether carvedilol...

Original Article

September 24, 2024


Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial
Woo Hyun Paik, Joo Kyung Park, Moon Jae Chung, et al.
Clin Mol Hepatol. 2025;31(1):119-130.

Background/Aims: A clinical unmet need persists for medications capable of modulating the progression of primary sclerosing cholangitis (PSC). This study aimed to assess the clinical feasibility of HK-660S (beta-lapachone) in...

Original Article

October 2, 2024


Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation
Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, et al.
Clin Mol Hepatol. 2025;31(1):131-146.

Background/Aims: This study aimed to identify the risk factors for chronic kidney disease (CKD) and end-stage renal disease (ESRD) following liver transplantation (LT), with a specific focus on tacrolimus levels...

Original Article

October 2, 2024


USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination
Sha Hu, Zhouxiang Wang, Kun Zhu, et al.
Clin Mol Hepatol. 2025;31(1):147-165.

Background/Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD) is a chronic liver disease characterized by hepatic steatosis. Ubiquitin-specific protease 29 (USP29) plays pivotal roles in hepatic ischemiareperfusion injury and hepatocellular carcinoma,...

Original Article

October 4, 2024


Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness
Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, et al.
Clin Mol Hepatol. 2025;31(1):166-178.

Background/Aims: The World Health Organization (WHO) aims to eliminate hepatitis C virus (HCV) by 2030; therefore, widespread HCV screening is required. The WHO recommends HCV self-testing (HCVST) as a new...

Original Article

October 11, 2024


Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments
Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, et al.
Clin Mol Hepatol. 2025;31(1):179-195.

Background/Aims: Evidence suggests that the gastrointestinal microbiome plays a significant role in the biology of metabolic dysfunction-associated steatotic liver disease (MASLD). However, it remains unclear whether disparities in the gut...

Original Article

October 15, 2024


Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma
Yang Liu, Fan Peng, Siyuan Wang, et al.
Clin Mol Hepatol. 2025;31(1):196-212.

Background/Aims: Early detection and effective prognosis prediction in patients with hepatocellular carcinoma (HCC) provide an avenue for survival improvement, yet more effective approaches are greatly needed. We sought to develop...

Original Article

October 17, 2024


Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial
Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, et al.
Clin Mol Hepatol. 2025;31(1):213-226.

Background/Aims: Treatment indications for patients with chronic hepatitis B (CHB) remain contentious, particularly for patients with mild alanine aminotransferase (ALT) elevation. We aimed to evaluate treatment effects in this patient...

Original Article

November 14, 2024


Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis
Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, et al.
Clin Mol Hepatol. 2025;31(1):227-239.

Background/Aims: With the obesity pandemic, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease and a leading cause of end-stage liver disease and liver-related deaths in the...

Original Article

November 21, 2024


Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis
Anja Tiede, Lena Stockhoff, Zhaoli Liu, et al.
Clin Mol Hepatol. 2025;31(1):240-255.

Background/Aims: Systemic Inflammation (SI) is considered a key mechanism in disease progression and development of complications in decompensated liver cirrhosis. SI is mainly driven by portal hypertension and bacterial translocation....
Current Issue
Volume 31(1); Jan 2025

Most-cited are based on citations from 2023 ~ 2025.

Original Article
1814
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng, Peng-Sheng Ting, Hirsh Trivedi, Aarshi Vipani, Walid Ayoub, Ju Dong Yang, Omer Liran, Brennan Spiegel, Alexander Kuo
Clin Mol Hepatol. 2023;29(3):721-732.   Published online March 22, 2023
View: 22649   Download: 1,613  Web of Science: 261  Crossref: 272
Review
1748
Global incidence and prevalence of nonalcoholic fatty liver disease
Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah
Clin Mol Hepatol. 2023;29(Suppl):S32-S42.   Published online December 14, 2022
View: 15959   Download: 589  Web of Science: 194  Crossref: 225
1735
MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George
Clin Mol Hepatol. 2023;29(Suppl):S17-S31.   Published online November 29, 2022
View: 20556   Download: 1,361  Web of Science: 141  Crossref: 155
Non-alcoholic fatty liver disease: Definition and subtypes
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Clin Mol Hepatol. 2023;29(suppl):S5-S16.   Published online December 28, 2022
View: 9647   Download: 567  Web of Science: 74  Crossref: 79
1714
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin
Clin Mol Hepatol. 2023;29(1):77-98.   Published online October 13, 2022
View: 12902   Download: 753  Web of Science: 70  Crossref: 76
Editorial
The latest global burden of liver cancer: A past and present threat
Joo Hyun Oh, Dae Won Jun
Clin Mol Hepatol. 2023;29(2):355-357.   Published online March 9, 2023
View: 6035   Download: 131  Web of Science: 45  Crossref: 48
Special Review
1849
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clin Mol Hepatol. 2023;29(4):831-843.   Published online August 25, 2023
View: 5706   Download: 390  Web of Science: 42  Crossref: 47
Review
1755
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective
Diyang Xie, Jieyi Shi, Jian Zhou, Jia Fan, Qiang Gao
Clin Mol Hepatol. 2023;29(2):206-216.   Published online December 22, 2022
View: 8659   Download: 508  Web of Science: 54  Crossref: 47
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik Yuen Chan
Clin Mol Hepatol. 2023;29(2):277-292.   Published online January 30, 2023
View: 8981   Download: 588  Web of Science: 41  Crossref: 45
1729
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Peter Konyn, Aijaz Ahmed, Donghee Kim
Clin Mol Hepatol. 2023;29(Suppl):S43-S57.   Published online November 22, 2022
View: 5404   Download: 191  Web of Science: 37  Crossref: 39
1770
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
Shang-Chin Huang, Chun-Jen Liu
Clin Mol Hepatol. 2023;29(2):320-331.   Published online February 1, 2023
View: 7322   Download: 452  Web of Science: 29  Crossref: 35
1797
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clin Mol Hepatol. 2023;29(2):252-262.   Published online March 10, 2023
View: 5533   Download: 272  Web of Science: 31  Crossref: 35
Risk factors in nonalcoholic fatty liver disease
Eunji Ko, Eileen L. Yoon, Dae Won Jun
Clin Mol Hepatol. 2023;29(Suppl):S79-S85.   Published online December 14, 2022
View: 5808   Download: 258  Web of Science: 29  Crossref: 34
Original Article
1760
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith
Clin Mol Hepatol. 2023;29(2):433-452.   Published online January 4, 2023
View: 7366   Download: 261  Web of Science: 31  Crossref: 33
Review
1740
Interaction between sarcopenia and nonalcoholic fatty liver disease
Sae Kyung Joo, Won Kim
Clin Mol Hepatol. 2023;29(Suppl):S68-S78.   Published online December 5, 2022
View: 6502   Download: 333  Web of Science: 31  Crossref: 31
1696
Development and prognosis of hepatocellular carcinoma in patients with diabetes
Takuma Nakatsuka, Ryosuke Tateishi
Clin Mol Hepatol. 2023;29(1):51-64.   Published online July 29, 2022
View: 6360   Download: 256  Web of Science: 26  Crossref: 29
1739
Comparison between obese and non-obese nonalcoholic fatty liver disease
Wah-Kheong Chan
Clin Mol Hepatol. 2023;29(Suppl):S58-S67.   Published online December 5, 2022
View: 6931   Download: 292  Web of Science: 22  Crossref: 28
1775
Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection
Chih-Lin Lin, Jia-Horng Kao
Clin Mol Hepatol. 2023;29(3):605-622.   Published online February 15, 2023
View: 5859   Download: 333  Web of Science: 23  Crossref: 28
Original Article
1818
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vincent Wai-Sun Wong, Ming-Whei Yu, Mindie H. Nguyen
Clin Mol Hepatol. 2023;29(3):705-720.   Published online May 8, 2023
View: 5626   Download: 282  Web of Science: 20  Crossref: 28
1703
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients
Yu Jun Wong, Chen Zhaojin, Guilia Tosetti, Elisabetta Degasperi, Sanchit Sharma, Samagra Agarwal, Liu Chuan, Chan Yiong Huak, Li Jia, Qi Xiaolong, Anoop Saraya, Massimo Primignani
Clin Mol Hepatol. 2023;29(1):135-145.   Published online September 5, 2022
View: 7364   Download: 372  Web of Science: 23  Crossref: 28
1698
Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly
Young Eun Chon, Seong Yong Park, Han Pyo Hong, Donghee Son, Jonghyun Lee, Eileen Yoon, Soon Sun Kim, Sang Bong Ahn, Soung Won Jeong, Dae Won Jun
Clin Mol Hepatol. 2023;29(1):120-134.   Published online August 12, 2022
View: 5649   Download: 233  Web of Science: 27  Crossref: 27
Review
1744
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
Jung Hwan Yu, Han Ah Lee, Seung Up Kim
Clin Mol Hepatol. 2023;29(Suppl):S136-S149.   Published online December 12, 2022
View: 5190   Download: 248  Web of Science: 26  Crossref: 26
Special Review
1854
Waiting for the changes after the adoption of steatotic liver disease
Eileen L. Yoon, Dae Won Jun
Clin Mol Hepatol. 2023;29(4):844-850.   Published online September 6, 2023
View: 3332   Download: 179  Web of Science: 20  Crossref: 26
Review
1691
Wnt signaling in liver regeneration, disease, and cancer
Gengyi Zou, Jae-Il Park
Clin Mol Hepatol. 2023;29(1):33-50.   Published online July 4, 2022
View: 7738   Download: 292  Web of Science: 23  Crossref: 25
1842
Recent advances in the management of hepatocellular carcinoma
Kamya Sankar, Jun Gong, Arsen Osipov, Steven A. Miles, Kambiz Kosari, Nicholas N. Nissen, Andrew E. Hendifar, Ekaterina K. Koltsova, Ju Dong Yang
Clin Mol Hepatol. 2024;30(1):1-15.   Published online July 21, 2023
View: 8241   Download: 413  Web of Science: 22  Crossref: 24
1728
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
Clin Mol Hepatol. 2023;29(Suppl):S157-S170.   Published online November 22, 2022
View: 5343   Download: 337  Web of Science: 24  Crossref: 23
1759
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
Clin Mol Hepatol. 2023;29(Suppl):S286-S301.   Published online December 28, 2022
View: 7093   Download: 273  Web of Science: 18  Crossref: 23
Original Article
1838
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
Clin Mol Hepatol. 2023;29(4):987-1001.   Published online July 5, 2023
View: 5536   Download: 312  Web of Science: 17  Crossref: 22
Review
1781
Acute hepatitis C virus infection: clinical update and remaining challenges
Chen-Hua Liu, Jia-Horng Kao
Clin Mol Hepatol. 2023;29(3):623-642.   Published online February 20, 2023
View: 7128   Download: 454  Web of Science: 21  Crossref: 22
1807
Acute-on-chronic liver failure: Terminology, mechanisms and management
Vinay Kumar BR, Shiv Kumar Sarin
Clin Mol Hepatol. 2023;29(3):670-689.   Published online March 20, 2023
View: 8074   Download: 819  Web of Science: 17  Crossref: 21

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS
FOLLOW US
Twitter
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 5567
TOTAL : 2380239
Close layer